Last update 21 Nov 2024
BLD-2660
Last update 21 Nov 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms Dazcapistat |
Target |
Mechanism Calpain1/2 inhibitors(Calpain1/2 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure
Molecular FormulaC21H18FN3O4 |
InChIKeyXYQHCMDVGIJOTA-UHFFFAOYSA-N |
CAS Registry2221010-42-8 |
Related
6
Clinical Trials associated with BLD-2660A Two-Part, Open Label, Complete Crossover Study to Compare the Tablet and Capsule Formulations of BLD-2660, Including a Food Effect Assessment of the Tablet Formulation, and to Assess Dose Proportionality Following Single Oral Doses of BLD-2660 in Tablet Formulation
A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate Pharmacodynamics, Pharmacokinetics, and Safety of BLD-2660 Administered Orally in Subjects with Idiopathic Pulmonary Fibrosis - B-2660-203
A phase 2 randomized double-blind placebo-controlled study to evaluate safety and antiviral activity of BLD-2660 in hospitalized subjects with recently diagnosed COVID-19 compared to standard of care treatment
100 Clinical Results associated with BLD-2660
Login to view more data
100 Translational Medicine associated with BLD-2660
Login to view more data
100 Patents (Medical) associated with BLD-2660
Login to view more data
1
Literatures (Medical) associated with BLD-266026 Nov 2021Current Drug TargetsQ4 · MEDICINE
Small-molecule Antiviral Agents in Ongoing Clinical Trials for COVID-19
Q4 · MEDICINE
Review
Author: Apaydın, Çağla Begüm ; Cihan-Üstündağ, Gökçe ; Çınar, Gözde
100 Deals associated with BLD-2660
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| COVID-19 | Phase 2 | US | 04 May 2020 | |
| COVID-19 | Phase 2 | BR | 04 May 2020 | |
| Idiopathic Pulmonary Fibrosis | Phase 2 | GB | 15 Dec 2019 | |
| Fibrosis, Liver | Phase 2 | AU | 11 Jul 2018 | |
| Pulmonary Fibrosis | Phase 2 | AU | 11 Jul 2018 | |
| Lung Diseases, Interstitial | Phase 2 | US | - |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 2 | 120 | imnjauiegs(hygvgsubnu) = diywcxndtx gfxniicgtv (vshavdlzvg, qmgtontmip - doqrvirnqx) View more | - | 06 Apr 2022 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free